Wire · opportunities
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
Revvity announced its agreement to acquire Human Cell Design (HCD), a France-based biotech specializing in human pancreatic beta cell models for metabolic disease drug discovery, aiming to combine HCD's cell models with Revvity's screening and analysis technologies to enhance drug discovery and preclinical research for diabetes, obesity, and related therapies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now access integrated human-relevant pancreatic beta cell models combined with advanced screening tools, opening new routes in metabolic disease drug discovery. This deal expands your toolkit for developing next-gen diabetes and obesity therapies faster and with greater precision.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics